BioSpace News Archive

BioInvent continued to make strong clinical and financial progress in Q1 2021. Positive interim results from the Phase 1/2a study of BI-1206 in B-cell non-Hodgkin’s lymphoma are very encouraging.

Continued strong order intake, with the strongest order intake figure for a first quarter in Mentice’s history on the back end of our strongest order intake for a fourth quarter ever.

Smith+Nephew, the global medical technology business, announces a new study showing that computer-guided technology for total hip arthroplasty – such as Smith+Nephew’s RI.HIP NAVIGATION – significantly reduces the risk of revision and increases patient satisfaction when using Smith+Nephew implants.

Calliditas Therapeutics AB announced that the U.S. Food and Drug Administration has accepted the submission and granted Priority Review for the New Drug Application for Nefecon, a down regulator of IgA1 for the treatment of IgA nephropathy The FDA has set a Prescription Drug User Fee Act goal date of September 15, 2021.

Integra LifeSciences Holdings Corporation, a leading global medical technology company, reported financial results for the first quarter ending March 31, 2021.

Sharps Compliance Corp., a leading full-service national provider of comprehensive waste management solutions including medical, pharmaceutical and hazardous, reported financial results for the third quarter ended March 31, 2021.

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, has announced their plan to add a blood-based 52-gene next generation sequencing (NGS) test to their portfolio of molecular testing based on a recent publication.

Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced the appointment of Joseph E. Gilliam to the Caris Board of Directors, effective April 12, 2021.

Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.752 billion during the first quarter of 2021.

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the following upcoming investor conferences in May: Bank of America Health Care Conference: fireside chat on Tuesday, May 11, 2021 at 10:15 am ET.